Two-year outcomes of intravitreal ranibizumab for myopic choroidal neovascularization

Purpose : To report the 2-year outcomes of intravitreal ranibizumab (IVR) for myopic choroidal neovascularization (mCNV). Cases and Methods ' Twenty-one patients with treatment-naive mCNV who visited Kyushu University Hospital from September 2013 to August 2016 underwent IVR and were followed up for 24 months or longer. Visual acuity, central retinal thickness (CRT), retinal thickness at CNV, thickness of CNV and the area of the CNV-related macular atrophy were retrospectively compared before and after IVR. CRT, retinal thickness at CNV, and thickness of CNV were evaluated with optical coherence tomography (OCT) and the area of macular atrophy was evaluated with fundus photographs. Results ! The mean age of the subjects was 68.9 years and the mean number of IVR was 5.7. Mean visual acuity significantly improved from 1 month after to 24 months after compared with baseline values (l, 3, 6, 12 months p<0.01, 18, 24 months p<0.05), but decreased gradually from 12 months. Mean CRT, retinal thickness at CNV, and thickness of CNV significantly improved at all points (p< 0.01). Mean area of macular atrophy became significantly enlarged 6 months after (p<0.0l) and expanded gradually during the observation period. Visual acuity after 2 years was correlated with visual acuity before treatment and the area of macular atrophy after 2 years. The amount of change in the macular atrophy area after 2 years was correlated with the number of IVR. Conclusion ; IVR resulted in improvement of retinal shape and regression of the CNV, but enlargement of macular atrophy was noted in the long term. There was a tendency that the area of macular atrophy became enlarged in patients who received frequent administration.